2-<<(N-t-Boc)-2-aminoethyl>sulphonyl>ethanol | 142604-13-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: 2-<<(N-t-Boc)-2-aminoethyl>sulphonyl>ethanol
• 英文别名: [2-(2-hydroxy-ethanesulfonyl)-ethyl]-carbamic acid tert-butyl ester；2-(2-tert-butoxycarbonylaminoethanesulfonyl)ethanol；tert-butyl-2-(2-hydroxyethylsulfonyl)ethylcarbamate；tert-butyl {2-[(2-hydroxyethyl)sulfonyl]ethyl}carbamate；tert-Butyl 2-(2-hydroxyethylsulfonyl)-ethylcarbamate；tert-butyl N-[2-(2-hydroxyethylsulfonyl)ethyl]carbamate
• CAS: 142604-13-5
• 化学式: C₉H₁₉NO₅S
• 分子量: 253.32
• InChiKey: BHYGDWGGIGRORN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-<<(N-t-Boc)-2-aminoethyl>sulphonyl>ethanol 在 氯磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以83%的产率得到sulfuric acid mono[2-(2-amino-ethanesulfonyl)-ethyl] ester
  参考文献：
  名称：

  用作制备活性染料的中间体的硫酸单-[2-(2-氨基-乙磺酸)-乙基]酯的新合成

  摘要：

  摘要 硫酸单-[2-(2-氨基-乙磺酰基)-乙基]酯 8 是活性染料的关键中间体，在温和条件下由 2-氨基乙硫醇和 2-溴乙醇分四步以良好的总收率制备。

  DOI：

  10.1081/scc-120004152
• 作为产物：
  描述：

  二-叔丁氧羰基-胱胺 在 sodium hydroxide 、 sodium tungstate 、 三丁基膦 、 碳酸氢钠 作用下， 以 乙醇 、 水 、 异丙醇 为溶剂， 反应 3.16h， 生成 2-<<(N-t-Boc)-2-aminoethyl>sulphonyl>ethanol
  参考文献：
  名称：

  An N-terminal method for peptide solubilisation

  摘要：

  Peptide-constructs of the form (solubilising peptide)-[NH(CH2)(2)SO2(CH2)(2)O-CO]-(insoluble peptide) were synthesised by Boc SPPS. The HPLC-purified peptide-constructs were cleaved with aqueous base to liberate the insoluble peptides as precipitates. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00309-9

文献信息

• AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1938823A1

  公开（公告）日：2008-07-02

  Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a pharmaceutically acceptable salt, or a hydrate or solvate of the prodrug or pharmaceutically acceptable salt, (wherein, R1 represents a hydrogen atom, or a C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or a divalent group comprising a sulfonyl group, and Y represents a residue of a compound represented by Y-OH comprising an alcoholic hydroxyl group, wherein said Y-OH is a camptothecin, a taxane, or an anticancer nucleotide).

  预防或治疗胰腺癌、卵巢癌或肝癌的本发明药剂包括下述式子所代表的水溶性前药，或者前药的药用可接受盐，或者前药或药用可接受盐的水合物或溶剂化合物， （其中， R1代表氢原子，或者C1-C6烷基； W代表包含三级胺基团或含磺酰基团的二价基团，以及 Y代表由Y-OH所代表的化合物残基，包括含有醇羟基的醇羟基化合物残基，其中所述的Y-OH是一种喜树碱、紫杉醇或抗癌核苷酸）。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：GENENTECH, INC.

  公开号：US20150031674A1

  公开（公告）日：2015-01-29

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , R c , R d , R e , n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
• NOVEL ANTICANCER CONCOMITANT DRUG
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1925309A1

  公开（公告）日：2008-05-28

  A cancer therapeutic agent according to the present invention comprises a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A: compound A1 represented by formula (1) below, or water-soluble prodrug A2 thereof; Compound B: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, a gemcitabine-type compound, a 5-FU-type compound, a taxane-type compound, a vinca alkaloid-type compound, an anticancer tyrosine kinase inhibitor compound, and an anticancer monoclonal antibody; (wherein, R11 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group; R12 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a hydroxyl group; R21 represents a hydrogen atom or a C1-C10 alkyl group which may comprise one to three substituents selected from Group B described below: Group B: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the aryl ring may comprise one to three substituents selected from the group consisting of a hydroxy group, a C1-C6 alkoxy group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, and a di-C1-C6 alkylamino group); and R22 represents a hydrogen atom, an amino group, or a C1-C6 alkyl group that may comprise one to three substituents selected from Group C described below, a C1-C6 alkoxy group that may comprise one to three substituents selected from Group C described below, a C1-C6 alkylthio group that may comprise one to three substituents selected from Group C described below, a mono-C1-C6 alkylamino group that may comprise one to three substituents selected from Group C described below, or a di-C1-C6 alkylamino group that may comprise one to three substituents selected from Group C described below: Group C: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the aryl ring may comprise one to three substituents selected from the group consisting of a hydroxy group, a C1-C6 alkoxy group, an amino group, a mono-C1-C6 alkylamino group, and a di-C1-C6 alkylamino group).

  根据本发明，一种癌症治疗剂包括以下所述的化合物A的组合物，或其药用可接受的盐，以及以下所述的化合物B的组合物，或其药用可接受的盐：化合物A：以下式（1）表示的化合物A1，或其水溶性前药A2；化合物B：选自铂类抗癌化合物、吉西他滨类化合物、5-氟尿嘧啶类化合物、紫杉醇类化合物、长春碱类化合物、抗癌酪氨酸激酶抑制剂化合物和抗癌单克隆抗体的化合物中的至少一种化合物；（其中，R11代表氢原子、卤原子或C1-C6烷基；R12代表氢原子、卤原子、C1-C6烷基或羟基；R21代表氢原子或C1-C10烷基，可能包括来自下文所述的B组的1至3个取代基：B组：C1-C6烷氧基、羟基、卤原子、氨基、单烷基氨基、双烷基氨基、C3-C7环烷基、杂环和芳基（芳基可能包括来自羟基、C1-C6烷氧基、卤原子、氨基、单烷基氨基和双烷基氨基的1至3个取代基）；R22代表氢原子、氨基或可能包括来自下文所述的C组的1至3个取代基的C1-C6烷基、可能包括来自下文所述的C组的1至3个取代基的C1-C6烷氧基、可能包括来自下文所述的C组的1至3个取代基的C1-C6烷硫基、可能包括来自下文所述的C组的1至3个取代基的单烷基氨基，或可能包括来自下文所述的C组的1至3个取代基的双烷基氨基：C组：C1-C6烷氧基、羟基、卤原子、氨基、C3-C7环烷基、杂环和芳基（芳基可能包括来自羟基、C1-C6烷氧基、氨基、单烷基氨基和双烷基氨基的1至3个取代基）。
• Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog
  作者：Jun Ohwada、Sawako Ozawa、Masami Kohchi、Hiroshi Fukuda、Chikako Murasaki、Hitomi Suda、Takeshi Murata、Satoshi Niizuma、Masao Tsukazaki、Kazutomo Ori、Kiyoshi Yoshinari、Yoshiko Itezono、Mika Endo、Masako Ura、Hiromi Tanimura、Yoko Miyazaki、Akira Kawashima、Shunsuke Nagao、Eitarou Namba、Koutarou Ogawa、Kazuko Kobayashi、Hisafumi Okabe、Isao Umeda、Nobuo Shimma

  DOI：10.1016/j.bmcl.2009.03.123

  日期：2009.5

  CH0793076 (1) is a novel hexacyclic camptothecin analog showing potent antitumor activity in various human caner xenograft models. To improve the water solubility of 1, water-soluble prodrugs were designed to generate an active drug 1 nonenzymatically, thus expected to show less interpatient PK variability than CPT-11. Among the prodrugs synthesized, 4c (TP300, hydrochloride) having a glycylsarcosyl

  CH0793076（1）是一种新颖的六环喜树碱类似物，其在各种人类癌异种移植模型中显示出有效的抗肿瘤活性。为了提高1的水溶性，设计了水溶性前药以非酶促方式生成活性药物1，因此预期其患者间PK变异性低于CPT-11。在合成的前药中，在C-20位置1处有一个糖基肌醇酯的4c（TP300，盐酸盐）具有很高的水溶性（> 10 mg / ml），在pH值4以下稳定，并且在体外生理pH值下迅速生成1。快速（约<1分钟）生成1TP300与血浆（小鼠，大鼠，狗和猴子）孵育后的结果也得到了证实。在各种人类癌症异种移植模型中，TP300显示出比CPT-11更宽的抗肿瘤谱和更强的抗肿瘤活性。
• Synthesis of a versatile purification handle for use with Boc chemistry solid phase peptide synthesis
  作者：Lynne E. Canne、Rachel L. Winston、Stephen B.H. Ken

  DOI：10.1016/s0040-4039(97)00651-5

  日期：1997.5

  The synthesis of a versatile handle for the purification of synthetic peptides is described. The Boc-aminoethylsulfonylethyloxycarbonyl handle is coupled to the NH2-terminus of the resin-bound peptide. Removal of the Boc group affords a free amine which can be derivatized with any of a variety of functionalities. Cleavage from the resin gives a peptide functionalized for covalent chemoselective reaction

  描述了用于纯化合成肽的通用手柄的合成。Boc-氨基乙基磺酰基乙氧基羰基手柄连接至树脂结合肽的NH 2-末端。Boc基团的除去提供了可以用多种官能团中的任何一种衍生的游离胺。从树脂上裂解得到功能化的肽，用于与柱支撑物进行共价化学选择性反应。通过用碱处理切割手柄，从柱子上洗脱所需的全长肽。